Novo Nordisk expands Wegovy® $499-per-month offering to additional cash-paying patients via the Wegovy® savings offer
Novo Nordisk has expanded its Wegovy® savings program, now offering the weight management medication at $499 per month to eligible cash-paying patients across all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg) at local retail pharmacies. Previously, this pricing was only available through the NovoCare® Pharmacy.
This expansion aims to improve accessibility and affordability while ensuring patients receive authentic, FDA-approved Wegovy® from reputable pharmacies, addressing concerns about risks associated with the compounding marketplace. The program reinforces Novo Nordisk's commitment to making innovative medicines more accessible to communities they serve.
Novo Nordisk ha ampliato il suo programma di risparmio per Wegovy®, offrendo ora il farmaco per la gestione del peso a 499 dollari al mese per i pazienti idonei che pagano in contante, disponibile in tutte le dosi (0,25 mg, 0,5 mg, 1 mg, 1,7 mg e 2,4 mg) presso le farmacie locali. In precedenza, questo prezzo era disponibile solo attraverso la NovoCare® Pharmacy.
Questa espansione mira a migliorare l'accessibilità e l'affordabilità, garantendo al contempo che i pazienti ricevano Wegovy® autentico, approvato dalla FDA, da farmacie affidabili, affrontando le preoccupazioni sui rischi associati al mercato della preparazione. Il programma rafforza l'impegno di Novo Nordisk a rendere i farmaci innovativi più accessibili alle comunità che servono.
Novo Nordisk ha ampliado su programa de ahorros para Wegovy®, ofreciendo ahora el medicamento para el control de peso a 499 dólares al mes para pacientes elegibles que pagan en efectivo, disponible en todas las dosis (0.25 mg, 0.5 mg, 1 mg, 1.7 mg y 2.4 mg) en farmacias locales. Anteriormente, este precio solo estaba disponible a través de la NovoCare® Pharmacy.
Esta expansión tiene como objetivo mejorar la accesibilidad y la asequibilidad, asegurando que los pacientes reciban Wegovy® auténtico, aprobado por la FDA, de farmacias de confianza, abordando preocupaciones sobre los riesgos asociados con el mercado de compuestos. El programa refuerza el compromiso de Novo Nordisk de hacer que los medicamentos innovadores sean más accesibles para las comunidades a las que sirven.
노보 노디스크는 웨고비® 절약 프로그램을 확대하여, 이제 모든 용량(0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg)에 대해 자격이 있는 현금 결제 환자에게 월 499달러에 체중 관리 약물을 제공하고 있습니다. 이전에는 이 가격이 노보케어® 약국을 통해서만 제공되었습니다.
이번 확장은 접근성과 경제성을 개선하는 동시에 환자들이 신뢰할 수 있는 약국에서 FDA 승인된 진짜 웨고비®를 받을 수 있도록 하여, 조제 시장과 관련된 위험에 대한 우려를 해결하는 것을 목표로 하고 있습니다. 이 프로그램은 노보 노디스크가 그들이 제공하는 지역 사회에 혁신적인 약물을 더 접근 가능하게 만들겠다는 약속을 강화합니다.
Novo Nordisk a élargi son programme d'économies pour Wegovy®, offrant désormais le médicament de gestion du poids à 499 $ par mois aux patients éligibles payant en espèces, disponible dans toutes les doses (0,25 mg, 0,5 mg, 1 mg, 1,7 mg et 2,4 mg) dans les pharmacies de détail locales. Auparavant, ce tarif n'était disponible que par l'intermédiaire de la NovoCare® Pharmacy.
Cette expansion vise à améliorer l'accessibilité et l'abordabilité tout en veillant à ce que les patients reçoivent un Wegovy® authentique, approuvé par la FDA, provenant de pharmacies réputées, abordant les préoccupations concernant les risques associés au marché des préparations. Le programme renforce l'engagement de Novo Nordisk à rendre les médicaments innovants plus accessibles aux communautés qu'ils servent.
Novo Nordisk hat sein Wegovy® Einsparungsprogramm erweitert und bietet nun das Medikament zur Gewichtsreduktion für 499 Dollar pro Monat für berechtigte Barzahler in allen Dosierungsstärken (0,25 mg, 0,5 mg, 1 mg, 1,7 mg und 2,4 mg) in lokalen Apotheken an. Zuvor war dieser Preis nur über die NovoCare® Pharmacy verfügbar.
Diese Erweiterung zielt darauf ab, die Zugänglichkeit und Erschwinglichkeit zu verbessern und gleichzeitig sicherzustellen, dass die Patienten authentisches, von der FDA zugelassenes Wegovy® von seriösen Apotheken erhalten, um Bedenken hinsichtlich der Risiken des Kompositionsmarktes zu adressieren. Das Programm verstärkt das Engagement von Novo Nordisk, innovative Medikamente für die von ihnen bedienten Gemeinschaften zugänglicher zu machen.
- None.
- None.
Insights
Novo Nordisk's expansion of the Wegovy® $499-per-month savings program to retail pharmacies represents a strategic enhancement to their commercialization approach for their blockbuster weight loss medication. By extending this fixed pricing beyond their proprietary NovoCare® Pharmacy to local pharmacies nationwide, the company is implementing a dual-channel strategy that addresses several market dynamics simultaneously.
The uniform pricing across all five dosage strengths (0.25mg through 2.4mg) is particularly significant as it removes financial barriers to dose escalation, which is essential for achieving optimal clinical efficacy. This flat pricing structure creates cost predictability for patients while potentially improving therapy adherence, a critical factor for long-term treatment success and recurring revenue.
This move appears strategically timed to address the growing competitive threat from compounded semaglutide alternatives that have gained traction amid previous supply constraints. By explicitly referencing FDA warnings about compounded products, Novo Nordisk is differentiating Wegovy® on safety and regulatory approval while simultaneously making their branded product more financially accessible.
For cash-paying patients who lack insurance coverage, this program creates a parallel access pathway with transparent pricing, potentially expanding the addressable market. This approach helps Novo Nordisk maintain market leadership in the increasingly competitive GLP-1 receptor agonist space while creating a more predictable revenue stream from the self-pay segment.
The company appears confident in their supply chain capabilities to support this expanded access, suggesting manufacturing capacity has improved sufficiently to meet potential increased demand, which had been a limiting factor in previous years.
- The Wegovy® savings offer is good for all dose strengths of Wegovy®
- Eligible cash-paying patients can redeem this offer at the retail pharmacy of their choice
"At Novo Nordisk, we are committed to developing innovative medicines and will continue to prioritize making them accessible to and affordable for the communities we serve," said Dave Moore, Executive Vice President,
Beyond NovoCare® Pharmacy, the Wegovy® savings program offers another avenue for people living with obesity to ensure they are receiving authentic, FDA-approved Wegovy® from reputable pharmacies, helping to avoid the significant risks that can be posed by the compounding marketplace, as warned by respected organizations, experts in the medical community, and the FDA. With an FDA-approved medicine like Wegovy®, healthcare professionals and patients can have clarity and confidence in knowing the medicine they are using has undergone rigorous review for safety, effectiveness, and quality. Patients can get the savings offer and find more information at Wegovy.com.
About the Wegovy® savings offer
The Wegovy® savings offer gives cash-paying patients or those with commercial insurance that does not cover obesity medicines access to a 28-day supply (one box) of Wegovy® for
About NovoCare® Pharmacy
NovoCare® Pharmacy provides cash-paying patients who have been prescribed Wegovy® with the ability to schedule shipments of their Wegovy® prescriptions directly to their home. Beyond convenient home delivery, NovoCare® also supports patients with benefit verification, refill reminders, and access to live support from a NovoCare® case manager. More information about NovoCare® Pharmacy is available at NovoCare.com.
Novo Nordisk is continuing to take multiple proactive measures to keep patients safe. More information can be found on semaglutide.com.
About Wegovy® (semaglutide) injection 2.4 mg
What is Wegovy®?
WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity:
- to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
- that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.
Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy® is safe and effective for use in children under 12 years of age.
Important Safety Information
What is the most important information I should know about Wegovy®? Wegovy® may cause serious side effects, including:
- Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
- Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Do not use Wegovy® if:
- you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy®
Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you:
- have or have had problems with your pancreas or kidneys
- have type 2 diabetes and a history of diabetic retinopathy
- have or have had depression, suicidal thoughts, or mental health issues
- are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
- are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant
- are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes into your breast milk
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
What are the possible side effects of Wegovy®?
Wegovy® may cause serious side effects, including:
- inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back
- gallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools
- increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery
- kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration
- severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away.
- serious allergic reactions. Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat
- change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy®
- increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes
- depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you
- food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures
The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.
Please see Medication Guide and Prescribing Information, including Boxed Warning, for Wegovy® at https://www.novo-pi.com/wegovy.pdf
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisk-expands-wegovy-499-per-month-offering-to-additional-cash-paying-patients-via-the-wegovy-savings-offer-302408528.html
SOURCE NOVO NORDISK INC.
FAQ
What is the new monthly cost of Wegovy® under Novo Nordisk's expanded savings program?
Which Wegovy® dose strengths are covered under the $499 monthly pricing?
Where can patients access Wegovy® under the new savings program?
How can patients access the Wegovy® savings offer from Novo Nordisk?
